Literature DB >> 3427279

Direct binding studies on ileal and cardiac muscarinic receptors.

A D Michel1, R L Whiting.   

Abstract

1 Functional studies have indicated that muscarinic receptors in cardiac tissue differ from those in the ileum. In the present study ileal and cardiac muscarinic receptors identified by [3H]-N-methyl scopolamine ([3H]-NMS) were characterized and the selectivity of currently available ileal and atrial selective antagonists determined. 2 In terms of the current functional classification of muscarinic receptors both ileal and cardiac muscarinic receptors were of the M2 subtype based upon their low affinity for pirenzepine. 3 Cyclohexylphenyl(2-piperidinoethyl)silanol (CPPS), a highly ileal selective antagonist in functional studies, was unable to distinguish between ileal and atrial muscarinic receptors identified in binding studies. Furthermore, although AF-DX 116 and dicyclomine were able to differentiate atrial and ileal muscarinic receptors, neither compound was more than 2 fold selective. These data indicate that it is not possible to subclassify ileal and atrial muscarinic receptors using direct ligand binding studies with these antagonists. 4 In circular ileal smooth muscle, apparent heterogeneity of the M2 muscarinic receptor population was observed. Thus AF-DX 116 identified two populations of sites with affinities differing by 30 fold. These two populations of M2 muscarinic receptors may represent the typical M2 muscarinic receptors identified in cardiac tissue and the more recently discovered 'gland type' M2 muscarinic receptors. 5 The circular ileal smooth muscle tissue homogenate was able to decrease dramatically the apparent affinity of adiphenine. This activity, which appeared to result from a phenylmethylsulphonylfluoride (PMSF) sensitive protease effect, should be considered when conducting studies using this tissue preparation and compounds of similar structure to adiphenine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3427279      PMCID: PMC1853717          DOI: 10.1111/j.1476-5381.1987.tb11379.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  STIMULANT ACTIONS OF VOLATILE ANAESTHETICS ON SMOOTH MUSCLE.

Authors:  H P RANG
Journal:  Br J Pharmacol Chemother       Date:  1964-04

Review 2.  Neurohumoral, hormonal, and drug receptors for the lower esophageal sphincter.

Authors:  R K Goyal; S Rattan
Journal:  Gastroenterology       Date:  1978-03       Impact factor: 22.682

3.  Antagonist discrimination between ganglionic and ileal muscarinic receptors.

Authors:  D A Brown; A Forward; S Marsh
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

4.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

6.  Three types of muscarinic receptors? [proceedings].

Authors:  R B Barlow; K N Burston; A Vis
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

7.  Two populations of binding sites for muscarinic antagonists in the rat heart.

Authors:  E C Hulme; C P Berrie; N J Birdsall; A S Burgen
Journal:  Eur J Pharmacol       Date:  1981-07-17       Impact factor: 4.432

8.  Regional and subcellular distribution of myocardial muscarinic cholinergic receptors.

Authors:  J W Wei; P V Sulakhe
Journal:  Eur J Pharmacol       Date:  1978-11-15       Impact factor: 4.432

9.  Pirenzepine distinguishes between different subclasses of muscarinic receptors.

Authors:  R Hammer; C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

10.  A study of the muscarinic receptor by gel electrophoresis.

Authors:  N J Birdsall; A S Burgen; E C Hulme
Journal:  Br J Pharmacol       Date:  1979-06       Impact factor: 8.739

View more
  9 in total

1.  The interaction of hexamethonium with muscarinic receptor subtypes in vitro.

Authors:  R M Eglen; A D Michel; C M Cornett; E A Kunysz; R L Whiting
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

2.  Binding of muscarine receptor antagonists to pig coronary smooth muscle.

Authors:  I Rinner; H N Doods; K J van Charldorp; D Davidesko; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

3.  Subclassification of atrial and intestinal muscarinic receptors of the rat--direct binding studies with agonists and antagonists.

Authors:  F Brunner
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

4.  Characterization of the muscarinic receptor subtype involved in phosphoinositide metabolism in bovine tracheal smooth muscle.

Authors:  A F Roffel; H Meurs; C R Elzinga; J Zaagsma
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

5.  The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function.

Authors:  K J Murray; P J England; T J Hallam; J Maguire; K Moores; M L Reeves; A W Simpson; T J Rink
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

6.  Functional and binding studies with muscarinic M2-subtype selective antagonists.

Authors:  S Lazareno; F F Roberts
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

7.  The human astrocytoma cell line 1321 N1 contains M2-glandular type muscarinic receptors linked to phosphoinositide turnover.

Authors:  E A Kunysz; A D Michel; R L Whiting; K Woods
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

8.  The interaction of methoctramine and himbacine at atrial, smooth muscle and endothelial muscarinic receptors in vitro.

Authors:  R M Eglen; W W Montgomery; I A Dainty; L K Dubuque; R L Whiting
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

9.  Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine.

Authors:  J E Souness; R Brazdil; B K Diocee; R Jordan
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.